We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy (PONS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03807479
Recruitment Status : Active, not recruiting
First Posted : January 17, 2019
Last Update Posted : September 10, 2022
Incyte Biosciences International Sàrl
Information provided by (Responsible Party):

Brief Summary:
This study will include patients suffering from chronic myeloid leukemia (CP-CML), who were treated with tyrosine kinase inhibitor (TKI, a substance that blocks the action of enzymes) in a previous therapy but which has not been effective. Patients will be treated with Ponatinib 30 mg in in this study. The aim of the study is to evaluate the safety and efficacy of Ponatinib as a second line treatment in patients failing or not tolerating first line therapy with any other approved TKIs. It is expected that Ponatinib, due to its efficacy, may be more effective as second line therapy than other approved TKIs and lead to improved overall survival. The effect will be determined by the molecular response rate (MMR) as the primary objective after 12 months of treatment. The safety of the drug will be evaluated on the basis if routine medical and laboratory examinations.

Condition or disease Intervention/treatment Phase
Leukemia, Myeloid, Chronic-Phase Drug: Ponatinib Phase 2

Detailed Description:

Despite significant progress in the treatment of patients with chronic phase CML, there is still need to further optimize therapy to reach the goal of disease eradication for almost all patients. In case of imatinib failure, dasatinib and nilotinib are effective treatment options after an individualized treatment selection. Although MMR rates of around 30% after 2 years of therapy are a significant achievement, options that may improve response rates in depth are still desirable. Ponatinib is a third generation TKI with very high anti-clonal activity in all CML phases. Moreover, it also eradicates most of the known and problematic mutations and only very few (compound) mutations may induce ponatinib-resistance.

Based on its favourable target spectrum, it is expected that Ponatinib may be more effective than 2nd line dasatinib or nilotinib in achieving early (i.e., at 6 months) cytogenetic and molecular responses in patients after inappropriate response to imatinib, and more effective as 2nd line treatment after failure of initial treatment with dasatinib or nilotinib than a cross-over between the 2nd generation TKIs. The basic hypothesis underlying therapeutic programs in CML is to be able to achieve meaningful and long-lasting suppression of the Philadelphia chromosome and breakpoint cluster region-abelson fusion gen (BCR-ABL). Complete cytogenetic responses have been associated with improved survival in CML, while major molecular responses are associated with improved event-free survival.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Clinical Trial With Ponatinib as a Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Prior First Line Tyrosine Kinase Inhibitor Treatment
Actual Study Start Date : December 11, 2018
Estimated Primary Completion Date : July 31, 2024
Estimated Study Completion Date : August 31, 2024

Arm Intervention/treatment
Experimental: Ponatinib
Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
Drug: Ponatinib
2 film-coated tablets à 15mg for oral administration on a daily basis
Other Name: Iclusig

Primary Outcome Measures :
  1. Major Molecular Response (MMR) of treatment [ Time Frame: by 12 moths ]
    To estimate the proportion of CP-CML patients with tyrosine kinase inhibitor (TKI)-resistance or intolerance to first line therapy with TKI, attaining MMR by 12 months of treatment with second line Ponatinib therapy.

Secondary Outcome Measures :
  1. Time to toxicity [ Time Frame: up to 24 months ]
    To evaluate the toxicity profile of ponatinib in patients with CML in chronic phase after one TKI failure toxicities will be followed up at each visit during the treatment phase and will be assessed using CTCAE v.5.0. Type of toxicity (hematologic or non-hematologic) along with the grading will be followed up on.

  2. Time to response [ Time Frame: at 3, 6, 9, 12, 18 and 24 months ]
    To estimate the time to CCyR, MMR, MCyR and MR4 for patients treated with Ponatinib as second line therapy for CP-CML (chronic phase-chronic myelogenous leukemia).

  3. Durations of response [ Time Frame: at 3, 6, 9, 12, 18 and 24 month ]
    To evaluate the duration of hematologic, cytogenetic and molecular response to Ponatinib after one TKI failure.

  4. Occurrence of BCR-ABL-mutations [ Time Frame: at 3, 6, 9, 12, 18 and 24 months ]
    To evaluate the occurrence of BCR-ABL-mutations in patients with failure of Ponatinib 2nd line therapy.

  5. Time to progression [ Time Frame: at 3, 6, 9, 12, 18 and 24 months ]
    To define the time to progression for patients with CML in chronic phase treated with Ponatinib after one TKI failure.

  6. Time to overall survival [ Time Frame: at 3, 6, 9, 12, 18 and 24 month ]
    To define the time to overall survival for patients with CML in chronic phase treated with Ponatinib after one TKI failure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients ≥18 years old
  2. Diagnosis of Ph-positive (by cytogenetics) or BCR-ABL-positive (by PCR) CP-CML
  3. Patients should have demonstrated to have

    • a failure of a prior 1st line TKI treatment with either imatinib, dasatinib or nilotinib. Failure is defined as per European LeukemiaNet (ELN) recommendations:

      • Less than Complete Hematologic Response (CHR) and/or Ph+ > 95% at or beyond 3 months
      • No cytogenetic response (Ph+>35%) and/or Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) >10% at or beyond 6 months
      • BCR-ABL (on international scale) >1% and/or PH+ >0%
      • Less than MMR at or beyond 18 months
      • Loss of response or development of mutations or other clonal chromosomal abnormalities at any time during the first line TKI treatment
    • or intolerance to prior TKI treatment defined as grade 3 or 4 toxicity, or persistent grade 2 toxicity despite optimal management including dose adjustment, or in a patient where dose reductions are considered to be not in the patient's best interest to obtain an adequate response. Intolerant patients should not have achieved or have lost major molecular response at the time of enrollment
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria:

  1. Any 1st line anti-CML treatment other than TKI (apart from therapy with hydroxyurea)
  2. Any 2nd line therapy with a tyrosine kinase inhibitor (>1 European Medicines Agency (EMA) approved TKI for CML, or any investigational non EMA-approved TKI)
  3. Concurrent participation in any other clinical trial involving another investigational drug within 4 weeks prior to enrollment and throughout participation in PONS-Study
  4. New York Heart Association (NYHA) cardiac class 3-4 heart disease
  5. Cardiac Symptoms within the past 12 months prior recruitment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03807479

Layout table for location information
University Hospital
Halle (Saale), Saxony-Anhalt, Germany, 06097
University Hospital RWTH Aachen,Clinic for Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Department IV
Aachen, Germany, 52074
Charité University Medicine Berlin - Medical Clinic, Department of Hematology, Oncology and Tumor Immunology
Berlin, Germany, 13353
University Hospital Essen gGmbH, Westdeutsches Tumorzentrum; Internal Medicine (Tumor Research)
Essen, Germany, 45122
University Medicine Greifswald, Clinic and Policlinic - Internal Medicine C - Hematology and Oncology
Greifswald, Germany, 17475
Asklepios Clinic St. Georg - Department of Oncology, Section Hematology
Hamburg, Germany, 20099
University Hospital Mannheim GmbH, III. Medical Clinic for Hematology and Oncology
Mannheim, Germany, 68167
University Hospital Giessen and Marburg GmbH, Institution department Clinic for Hematology, Oncology and Immunology
Marburg, Germany, 35043
UKRUB University Hospital of Ruhr-University Bochum, Clinic for Hematology and Oncology
Minden, Germany, 32429
University Hospital Ulm - Department for internal medicine III
Ulm, Germany, 89081
Sponsors and Collaborators
Incyte Biosciences International Sàrl
Layout table for investigator information
Principal Investigator: Philipp le Coutre, Prof. Charité Berlin - Department of Hematology, Oncology and Tumor Immunology
Layout table for additonal information
Responsible Party: GWT-TUD GmbH
ClinicalTrials.gov Identifier: NCT03807479    
Other Study ID Numbers: PONS_11272
First Posted: January 17, 2019    Key Record Dates
Last Update Posted: September 10, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GWT-TUD GmbH:
CML in chronic phase
Chronic Myelogenous Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action